Naltrexone: A Pan-Addiction Treatment?

CNS Drugs

Volumn 30, Issue 8, 2016, Pages 719-733

  Aboujaoude, Elias ^a   Salame, Wael O ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CENTRAL STIMULANT AGENT; ENDORPHIN; NALTREXONE; NICOTINE; OPIATE; PLACEBO; NARCOTIC ANTAGONIST;

ADDICTION; ALCOHOL USE DISORDER; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; GAMBLING; HUMAN; KLEPTOMANIA; MEDLINE; MORBIDITY; OPIATE ADDICTION; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TRICHOTILLOMANIA; ANIMAL; DRUG DEPENDENCE; EVIDENCE BASED MEDICINE; PROCEDURES;

ANIMALS; BEHAVIOR, ADDICTIVE; EVIDENCE-BASED MEDICINE; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE-RELATED DISORDERS;

EID: 84978039222     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0373-0     Document Type: Review

References (71)

1. Moore EA, Wilkinson S. The promise of low dose naltrexone therapy, potential benefits in cancer, autoimmune, neurological and infectious disorders. McFarland; 2008. http://www.elainemoore.com/Books/NEWThePromiseofLDNTherapy/tabid/102/Default.aspx. Last visited 27 Feb 2016.
2. Food and Drug Association. Revia label and approval history. FDA Website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Last visited 27 Feb 2016.
3. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003687/WC500185583.pdf. Last visited 4 Jun 2016.
4. Therapeutic Goods Administration. https://search.tga.gov.au/s/search.html?collection=tga-websites-web&query=naltrexone. Last visited 4 Jun 2016.
5. Schecter AJ, Friedman JG, Grossman DJ. Clinical use of naltrexone (EN-1639A): part I: safety and efficacy in pilot studies. Am J Drug Alcohol Abuse. 1974;1(2):253–69.
6. Unterwald EM. Naltrexone in the treatment of alcohol dependence. J Addict Med. 2008;2(3):121–7.
7. Burattini C, Burbassi S, Aicardi G, Cervo L. Effects of naltrexone on cocaine- and sucrose-seeking behaviour in response to associated stimuli in rats. Int J Neuropsychopharmacol. 2008;11(1):103–9.
8. Murray JE, Belin-rauscent A, Simon M, et al. Basolateral and central amygdala differentially recruit and maintain dorsolateral striatum-dependent cocaine-seeking habits. Nat Commun. 2015;6:10088.
9. D’souza MS, Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract. 2011;6(1):4–16.
10. Food and Drug Administration. Revia drug insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf. Last visited 4 Jun 2016.
11. Food and Drug Administration. Vivitrol drug insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021897s020s023lbl.pdf. Last visited 25 Feb 2016.
12. Gastfriend DR. Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci. 2011;1216:144–66.
13. Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006;101(Suppl):142–51.
14. Petry NM. Should the scope of addictive behaviors be broadened to include pathological gambling? Addiction. 2006;101(S1):152–60.
15. Blanco C, Moreyra P, Nunes EV, et al. Pathological gambling: addiction or obsession? Semin Clin Neuropsychiatry. 2001;6:167–76.
16. Potenza MN, Fiellin DA, Heninger GR, et al. Gambling: an addictive behavior with health and primary care implications. J Gen Int Med. 2002;17:721–32.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1987.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
19. Aboujaoude E. Problematic Internet use: an overview. World Psychiatry. 2010;9(2):85–90.
20. Aboujaoude E. Compulsive buying disorder: a review and update. Curr Pharm Des. 2014;20(25):4021–5.
21. Verdejo-garcía A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev. 2008;32(4):777–810.
22. Hou H, Tian M, Zhang H. Positron emission tomography molecular imaging of dopaminergic system in drug addiction. Anat Rec (Hoboken). 2012;295(5):722–33.
23. Limbrick-Oldfield EH, Van Holst RJ, Clark L. Fronto-striatal dysregulation in drug addiction and pathological gambling: consistent inconsistencies? Neuroimage Clin. 2013;2:385–93.
24. Luijten M, Machielsen MW, Veltman DJ, Hester R, De Haan L, Franken IH. Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people with substance dependence and behavioural addictions. J Psychiatry Neurosci. 2014;39(3):149–69.
25. Olmstead MC, Ouagazzal AM, Kieffer BL. Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. PLoS ONE. 2009;4(2):e4410.
26. Mick I, Myers J, Ramos AC, et al. Blunted endogenous opioid release following an oral amphetamine challenge in pathological gamblers. Neuropsychopharmacology. 2016;41(7):1742–50.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
28. Volpicelli JR, Alterman AI, Hayashida M, O’brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–80.
29. O’Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–7.
30. Kranzler HR, Tennen H, Armeli S, et al. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol. 2009;29(4):350–7.
31. O’Malley SS, Corbin WR, Leeman RF, et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry. 2015;76(2):e207–13.
32. Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530–4.
33. Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003;23(3):294–304.
34. Ahmadi J, Kampman KM, Oslin DM, et al. Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. Am J Addict. 2009;18(1):81–6.
35. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565–73.
36. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381–7.
37. Heinälä P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21(3):287–92.
38. Hernandez-Avila CA, Song C, Kuo L, et al. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006;30(5):860–5.
39. Krystal JH, Cramer JA, Krol WF, et al. Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734–9.
40. Killeen TK, Brady KT, Gold PB, et al. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004;28(11):1710–7.
41. Knox PC, Donovan DM. Using naltrexone in inpatient alcoholism treatment. J Psychoactive Drugs. 1999;31(4):373–88.
42. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587–93.
43. Huang MC, Chen CH, Yu JM, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol. 2005;10(3):289–92.
44. Davidson D, Saha C, Scifres S, et al. Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Addict Behav. 2004;29(6):1253–8.
45. Galarza NJ, Díaz Ramírez D, Guzmán F, et al. The use of naltrexone to treat ambulatory patients with alcohol dependence. Bol Asoc Med P R. 1997;89(10–12):157–60.
46. Gastpar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol. 2002;22(6):592–8.
47. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28(7):1051–9.
48. Garbutt JC, Kranzler HR, O’malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.
49. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998;22(5):1074–9.
50. Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat. 2004;26(4):285–94.
51. National Research Council Committee on Clinical Evaluation of. Narcotic antagonists. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Arch Gen Psychiatry. 1978;35(3):335–40.
52. San L, Pomarol G, Peri JM, et al. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict. 1991;86(8):983–90.
53. Lerner A, Sigal M, Bacalu A, et al. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci. 1992;29(1):36–43.
54. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210–8.
55. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence. Lancet. 2011;378(9792):665.
56. King A, Cao D, Zhang L, Rueger SY. Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial. Addiction. 2013;108(10):1836–44.
57. King AC, Cao D, O’Malley SS, et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32(5):630–6.
58. Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis. 1999;18(1):31–40.
59. Wewers ME, Dhatt R, Tejwani GA. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl). 1998;140(2):185–90.
60. King A, de Wit H, Riley RC, et al. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006;8(5):671–82.
61. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26(2):167–80.
62. Jayaram-lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165(11):1442–8.
63. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914–21.
64. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69(5):783–9.
65. Grant JE, Kim SW, Odlaug BL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry. 2009;65(7):600–6.
66. Grant JE, Odlaug BL, Schreiber LR, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(1):134–8.
67. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol. 2001;21(6):632–4.
68. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry. 1987;22(1):35–42.
69. Knopman DS, Hartman M. Cognitive effects of high-dose naltrexone in patients with probable Alzheimer’s disease. J Neurol Neurosurg Psychiatr. 1986;49(11):1321–2.
70. Substance Abuse and Mental Health Service Administration (SAMHSA). Naltrexone. Last updated: 11/10/2015. http://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone. Last visited 22 Feb 2016.
71. Lucey MR, Silverman BL, Illeperuma A, O’brien CP. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res. 2008;32(3):498–504.